Mustang Bio Inc (MBIO) concluded trading on Thursday at a closing price of $1.24, with 17.84 million shares of worth about $22.12 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -91.55% during that period and on April 24, 2025 the price saw a loss of about -6.72%. Currently the company’s common shares owned by public are about 3.31M shares, out of which, 1.96M shares are available for trading.
Stock saw a price change of -7.46% in past 5 days and over the past one month there was a price change of -12.68%. Year-to-date (YTD), MBIO shares are showing a performance of -85.99% which decreased to -92.71% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.13 but also hit the highest price of $65.00 during that period. The average intraday trading volume for Mustang Bio Inc shares is 195.31K. The stock is currently trading -6.03% below its 20-day simple moving average (SMA20), while that difference is down -27.95% for SMA50 and it goes to -86.89% lower than SMA200.
Mustang Bio Inc (NASDAQ: MBIO) currently have 3.31M outstanding shares and institutions hold larger chunk of about 2.83% of that.
The stock has a current market capitalization of $4.09M and its 3Y-monthly beta is at 2.16. It has posted earnings per share of -$43.66 in the same period. It has Quick Ratio of 0.68. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MBIO, volatility over the week remained 11.01% while standing at 9.72% over the month.
Analysts are in expectations that Mustang Bio Inc (MBIO) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on May 18, 2021 offering a Buy rating for the stock and assigned a target price of $11 to it. Coverage by B. Riley FBR stated Mustang Bio Inc (MBIO) stock as a Buy in their note to investors on October 02, 2020, suggesting a price target of $9 for the stock. On November 20, 2019, Cantor Fitzgerald Initiated their recommendations, while on August 13, 2019, H.C. Wainwright Initiated their ratings for the stock with a price target of $7. Stock get an Overweight rating from Cantor Fitzgerald on June 21, 2019.
